Clinical Trial Update: Treatment of Schizophrenia With an Omega-3 Fatty Acid (EPA) and Antioxidants [Phase 2, Phase 3]

View source ↗

Summary

An update on Phase 2 and Phase 3 trials evaluating whether omega-3 fatty acid EPA, combined with antioxidants, can treat schizophrenia and related psychotic dis…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Psychotic Disorders
• Schizoaffective Disorder
• Schizophrenia
• Schizophreniform Disorder

Drugs mentioned

• Eicosapentaenoic acid (EPA) with antioxidants (eicosapentaenoic acid)

Snippet

Sponsor: University Hospital, Aker | Conditions: Schizophrenia, Schizophreniform Disorders | Phase 2, Phase 3 | Status: COMPLETED